2020
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, Mansukhani MM, Murty VV, Hsiao S, Alobeid B, Bhagat G. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica 2020, 107: 201-210. PMID: 33297669, PMCID: PMC8719101, DOI: 10.3324/haematol.2020.267294.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildEpstein-Barr Virus InfectionsFemaleHIV InfectionsHumansImmunophenotypingIn Situ Hybridization, FluorescenceMaleMiddle AgedPlasmablastic LymphomaYoung AdultConceptsPlasmablastic lymphomaJAK/STATSolid organ allograft recipientsTargetable oncogenic pathwaysOrgan allograft recipientsAllograft recipientsComprehensive histopathologicEBV infectionHIV infectionPlasmablastic myelomaClinical outcomesClinicopathologic featuresYears postdiagnosisAggressive neoplasmDisease subsetsEBV- casesImmunophenotypic heterogeneityImmunophenotypic evaluationMAP kinaseImmunocompromised individualsMYC rearrangementDisease pathogenesisPhenotypic spectrumNotch pathway genesOncogenic pathways
2016
Post‐transplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger DD & Gross TG
Radeski D, Montanari F, Alobeid B, O'Connor OA, Bhagat G. Post‐transplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger DD & Gross TG. British Journal Of Haematology 2016, 179: 856-857. PMID: 27471184, DOI: 10.1111/bjh.14272.Peer-Reviewed Original Research
2015
Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series
Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildChild, PreschoolCombined Modality TherapyEpstein-Barr Virus InfectionsFemaleHumansImmunosuppressive AgentsInfantLymphoproliferative DisordersMaleMiddle AgedMultivariate AnalysisOrgan TransplantationPostoperative ComplicationsPrognosisRisk AssessmentRituximabSeverity of Illness IndexYoung AdultConceptsPost-transplant lymphoproliferative disorderECOG scoreElderly patientsPediatric patientsLymphoproliferative disordersEastern Cooperative Oncology Group scoreECOG score 0Setting of immunosuppressionDecade of diagnosisNew prognostic scoreSingle-institution seriesHigh-risk groupAdult patientsOverall survivalPrognostic factorsPrognostic scoreInstitution seriesSingle institutionScore 0Tissue allograftsPatientsLarge seriesRisk categoriesHeterogeneous groupRecursive partitioning model